Novacea
11
0
0
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 85/100
18.2%
2 terminated/withdrawn out of 11 trials
50.0%
-36.5% vs industry average
9%
1 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer
Role: collaborator
A New Formulation of Calcitriol (DN-101) in Patients With Advanced Malignancies
Role: lead
ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere
Role: lead
A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer
Role: lead
DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])
Role: lead
AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme
Role: lead
Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer
Role: lead
Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia
Role: lead
Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Role: lead
Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS)
Role: lead
Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004
Role: lead
All 11 trials loaded